X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (375) 375
middle aged (185) 185
oncology (177) 177
female (165) 165
male (156) 156
adult (155) 155
hematology (140) 140
aged (135) 135
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (119) 119
chronic myeloid-leukemia (114) 114
chronic myelogenous leukemia (110) 110
imatinib mesylate (90) 90
human necessities (86) 86
hygiene (86) 86
medical or veterinary science (86) 86
preparations for medical, dental, or toilet purposes (86) 86
benzamides (82) 82
chronic myeloid leukemia (82) 82
antineoplastic agents - therapeutic use (81) 81
prognosis (80) 80
index medicus (77) 77
leukemia, myelogenous, chronic, bcr-abl positive - genetics (76) 76
philadelphia chromosome (71) 71
treatment outcome (69) 69
leukemia, myelogenous, chronic, bcr-abl positive - therapy (59) 59
leukemia, myelogenous, chronic, bcr-abl positive - pathology (57) 57
piperazines - therapeutic use (57) 57
pyrimidines - therapeutic use (56) 56
chemistry (55) 55
heterocyclic compounds (55) 55
metallurgy (55) 55
organic chemistry (55) 55
therapy (55) 55
interferon-alpha - therapeutic use (54) 54
leukemia (54) 54
acyclic or carbocyclic compounds (47) 47
cancer (47) 47
specific therapeutic activity of chemical compounds ormedicinal preparations (47) 47
adolescent (44) 44
remission induction (44) 44
aged, 80 and over (42) 42
research (42) 42
blast crisis (41) 41
acute lymphoblastic-leukemia (40) 40
drug therapy (40) 40
antineoplastic combined chemotherapy protocols - therapeutic use (39) 39
interferon-alpha (39) 39
philadelphia-chromosome (39) 39
animals (38) 38
bcr-abl (37) 37
bone-marrow transplantation (37) 37
care and treatment (36) 36
follow-up studies (36) 36
fusion proteins, bcr-abl - genetics (36) 36
medicine, general & internal (35) 35
protein-tyrosine kinases - antagonists & inhibitors (34) 34
leukemia, myelogenous, chronic, bcr-abl positive - mortality (33) 33
survival (32) 32
protein kinase inhibitors - therapeutic use (30) 30
survival analysis (30) 30
abl tyrosine kinase (29) 29
cells (29) 29
dose-response relationship, drug (29) 29
expression (29) 29
mice (29) 29
survival rate (29) 29
cytogenetic responses (27) 27
tyrosine kinase inhibitor (25) 25
antineoplastic agents - adverse effects (24) 24
drug administration schedule (24) 24
imatinib (23) 23
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (23) 23
article (22) 22
cytogenetic response (22) 22
drug resistance, neoplasm (22) 22
genetic aspects (22) 22
inhibitor (22) 22
leukemia, myelogenous, chronic, bcr-abl positive - blood (22) 22
pyrimidines - administration & dosage (22) 22
pyrimidines - adverse effects (22) 22
tumor cells, cultured (22) 22
bone marrow - pathology (21) 21
colony-stimulating factor (21) 21
disease progression (21) 21
interferon type i - therapeutic use (21) 21
myelofibrosis (21) 21
time factors (21) 21
antineoplastic agents - administration & dosage (20) 20
chronic granulocytic-leukemia (20) 20
chronic-phase (20) 20
hematology, oncology and palliative medicine (20) 20
interferon (20) 20
mutation (20) 20
recombinant proteins (20) 20
abridged index medicus (19) 19
health aspects (19) 19
hematopoietic stem cell transplantation (19) 19
leukemia, myeloid, chronic-phase - drug therapy (19) 19
low-dose cytarabine (19) 19
piperazines - administration & dosage (19) 19
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (802) 802
French (32) 32
German (15) 15
Chinese (7) 7
Portuguese (4) 4
Spanish (3) 3
Danish (2) 2
Korean (2) 2
Slovenian (2) 2
Greek (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1995, ISBN 1853172162, ix, 445
Book
1995, Cancer treatment and research, ISBN 0792336364, Volume CTAR80., xii, 387
Book
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, ISSN 1520-4391, 2009, Volume 2009, Issue 1, pp. 461 - 476
Given its relative rarity, it may at first seem surprising that chronic myeloid leukemia (CML) has garnered so much attention over the last decade. Yet, the... 
Piperazines - administration & dosage | Drugs, Investigational - pharmacology | Epigenesis, Genetic | Humans | Neoplasm Proteins - physiology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Salvage Therapy | Drugs, Investigational - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Structure-Activity Relationship | Antineoplastic Agents - administration & dosage | Drug Delivery Systems | Dose-Response Relationship, Drug | Drug Design | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Biological Transport - drug effects | Piperazines - pharmacokinetics | Neoplasm Proteins - genetics | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Protein Kinase Inhibitors - pharmacokinetics | Protein Kinase Inhibitors - classification | Pyrimidines - administration & dosage | Piperazines - therapeutic use | Signal Transduction - genetics | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - physiology | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - pharmacokinetics | Signal Transduction - physiology | Protein Kinase Inhibitors - pharmacology | Benzamides | Drug Resistance, Neoplasm - drug effects | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
1999, Basic and clinical oncology, ISBN 9780824799014, Volume 16, xi, 442
Book
The New England Journal of Medicine, ISSN 0028-4793, 06/2006, Volume 354, Issue 24, pp. 2531 - 2541
Journal Article
2004, Hematology/oncology clinics of North America, Volume 18, no. 3., xvi p., p. [525]-782
Book
1993, Medical intelligence unit (Unnumbered), ISBN 187970286X, 113
Book
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 612 - 621
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 22, pp. 2075 - 2088
Ponatinib was developed to overcome resistance to the tyrosine kinase inhibitors used to treat leukemias that are positive for the Philadelphia chromosome. In... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, GENERAL & INTERNAL | RESPONSE CRITERIA | KINASE DOMAIN MUTATIONS | DIAGNOSED CHRONIC-PHASE | TYROSINE KINASE | INTERNATIONAL-WORKING-GROUP | FOLLOW-UP | CLINICAL RESISTANCE | BCR-ABL INHIBITOR | CHRONIC MYELOID-LEUKEMIA | Amylases - blood | Lipase - blood | Follow-Up Studies | Humans | Middle Aged | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Imidazoles - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Drug Resistance, Neoplasm | Male | Structure-Activity Relationship | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Protein-Tyrosine Kinases - genetics | Antineoplastic Agents - adverse effects | Pyridazines - administration & dosage | Aged, 80 and over | Adult | Female | Pyridazines - adverse effects | Imidazoles - adverse effects | Antineoplastic Agents - chemistry | Pancreatitis - chemically induced | Pyridazines - chemistry | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - antagonists & inhibitors | Aged | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Patient outcomes | BCR-ABL tyrosine kinase inhibitors | Dosage and administration | Genetic aspects | Acute lymphocytic leukemia | Research | Drug therapy | Tyrosine | BCR protein | Acute lymphatic leukemia | Myeloid leukemia | Leukemia | Pancreatitis | Abl protein | Chronic myeloid leukemia | Lymphatic leukemia | Lipase | Kinases | Philadelphia chromosome | Proteins | Myelosuppression | Fusion protein | Protein-tyrosine kinase | Binding sites | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 7, pp. 789 - 796
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2012, Volume 366, Issue 9, pp. 799 - 807
Journal Article